CHAM
CRSP icon

Clear Harbor Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Clear Harbor Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-730
Closed -$61.1K – 404
2020
Q3 		$61.1K Buy
+730
New +$64.8K 0.01% 363
2020
Q1 		– Sell
-730
Closed -$44.5K – 360
2019
Q4 		$44.5K Buy
+730
New +$39.9K 0.01% 420

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Clear Harbor Asset Management's CRSP Position: Q4 2020 in Review

Clear Harbor Asset Management sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 730 shares — an estimated $61.1K sold.

Clear Harbor Asset Management first reported a position in CRSP in Q4 2019 and held it in 2 quarters. The position peaked at $61.1K in Q3 2020. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • Clear Harbor Asset Management reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Clear Harbor Asset Management sold 730 CRISPR Therapeutics shares in Q4 2020, an estimated $61.1K.
  • Clear Harbor Asset Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 2 quarters.
  • Clear Harbor Asset Management's CRISPR Therapeutics position peaked at $61.1K in Q3 2020.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Clear Harbor Asset Management's 13F filing for Q4 2020, filed 4 Feb 2021.